Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

AIDS (London, England) - 3 May 2002

Prado Julia G, Wrin Terri, Beauchaine Jeff, Ruiz Lidia, Petropoulos Christos J, Frost Simon D W, Clotet Bonaventura, D'Aquila Richard T, Martinez-Picado Javier

Abstract excerpt

OBJECTIVES: To evaluate protease inhibitor (PI) cross-resistance and reductions in replication capacity conferred by amprenavir-selected mutations. METHODS: HIV-1IIIB variants derived from passage in increasing concentrations of amprenavir were studied, as well as 3'Gag/protease recombinants derived from them. These strains progressively accumulated mutations at codons 10, 46, 47, 50 and 84 in the protease as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Furans

Share to Genes, gag

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Pyrimidinones

Source

Identifiers

PMID: 11953467
DOI: 10.1097/00002030-200205030-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.PMID 11953467Read ↗

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.Semantic proximity Read ↗

Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.Semantic proximity Read ↗

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.Semantic proximity Read ↗

Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.Semantic proximity Read ↗

Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.Semantic proximity Read ↗

Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?Semantic proximity Read ↗

Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.Semantic proximity Read ↗

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

Protease inhibitor resistance update: where are we now?Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.